# Alpha Teknova, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alpha Teknova, Inc.). ## Overview Alpha Teknova makes custom and catalog reagents used to discover, develop, and commercialize therapies, vaccines, and molecular diagnostics. Its products are designed for life sciences customers that need high-quality, made-to-order formulations with short turnaround times and consistent manufacturing at scale. The company serves more than 3,000 customers across pharmaceutical and biotechnology companies, CDMOs, diagnostics franchises, and academic and government labs. Teknova’s business is built around configurable manufacturing processes and quality systems that support customers from early research through GMP and commercialization. ## Products & services • Custom and made-to-order critical reagents • Catalog RUO products for life sciences research • GMP-grade reagents for development and production • Molecular diagnostics reagents and formulations • Reagents for cell and gene therapy workflows • Support for rapid custom manufacturing and fulfillment - **Custom critical reagents** (55%) — Customer-specified reagent formulations made to order for research, development, and commercialization workflows. - **Catalog RUO products** (25%) — Standard research-use-only reagents sold from the company’s catalog for routine life sciences applications. - **GMP-grade reagents** (10%) — Manufactured reagents used in regulated development and production environments for therapeutic programs. - **Molecular diagnostics reagents** (5%) — Reagents and formulations used by diagnostics customers in assay development and commercialization. - **Other life sciences reagents and services** (5%) — Adjacencies such as specialized formulations, support services, and smaller product lines. - Custom and made-to-order critical reagents - Catalog RUO products for life sciences research - GMP-grade reagents for development and production - Molecular diagnostics reagents and formulations - Reagents for cell and gene therapy workflows - Rapid custom manufacturing and fulfillment support ## Customers Teknova sells into the full life sciences development chain, so its customers include early-stage research labs as well as commercial manufacturers. The largest buyers are pharmaceutical and biotechnology companies that use its reagents in discovery, process development, and production of novel therapies and vaccines. It also serves CDMOs, in vitro diagnostics franchises, and academic and government research institutions that need reliable, fast-turn custom formulations. Customer demand is tied to the success of their own programs, regulatory progress, and end-market adoption, which makes Teknova’s revenue dependent on the health of the broader biotech funding and development cycle. - **Pharmaceutical and biotechnology companies** (primary) — Buy custom and GMP-grade reagents for discovery, development, and commercialization of therapeutic programs. - **Contract development and manufacturing organizations** (primary) — Purchase reliable reagent inputs for client projects where consistency, scale, and turnaround time matter. - **In vitro diagnostics franchises** (secondary) — Use Teknova formulations in assay development and commercialization for molecular diagnostics. - **Academic and government research institutions** (secondary) — Buy catalog RUO products and custom reagents for research workflows and grant-funded projects. - **Cell and gene therapy developers** (primary) — Need specialized reagents for high-growth therapeutic development and manufacturing workflows. - Pharmaceutical and biotechnology companies buying reagents for R&D and production - CDMOs needing consistent custom formulations for client programs - In vitro diagnostics franchises developing and commercializing assays - Academic and government research institutions purchasing RUO reagents - Cell and gene therapy developers needing specialized workflow reagents - Customers value speed, quality, and reproducibility over in-house production ## Geography Teknova is heavily concentrated in the United States, where 94.4% of 2025 revenue came from U.S. customers. International sales remain small but are growing faster than domestic sales, and management specifically highlights Europe as a medium- to long-term expansion opportunity. Reported international revenue is currently driven mainly by the United Kingdom, Canada, and Singapore, which indicates a limited but diversified early overseas footprint. The company’s manufacturing and operating base is in Hollister, California, so geography matters both for customer access and for the logistics of short-turn custom fulfillment. - **United States** (94.4%) - **International** (5.6%) — Primarily derived from the United Kingdom, Canada, and Singapore. - United States accounted for 94.4% of 2025 revenue - International revenue was 5.6% of 2025 revenue - International sales were mainly from the United Kingdom, Canada, and Singapore - Management sees Europe as a key expansion market - Hollister, California is the principal operating and manufacturing base - Geographic expansion depends on distributors, local manufacturing, or acquisitions ## Strategy Teknova’s strategy centers on operational excellence: investing in automation, facilities, and manufacturing infrastructure to improve capacity, reduce turnaround time, and support custom production at scale. Management is also trying to deepen customer loyalty by maintaining quality, service, and reliability, which is important because many products become embedded in customers’ workflows and are hard to replace. A second priority is selective geographic expansion, especially into Europe, where the company believes local supply is insufficient for customer-specified formulations with short lead times. The company is also open to partnerships, distribution relationships, and acquisitions that could add capabilities and broaden its addressable market. - **Operational excellence and capacity expansion** (short-term) — Fast, reliable custom manufacturing is the core competitive advantage and supports repeat business. - **Customer retention and workflow embedment** (medium-term) — Products that become embedded in customer processes create recurring demand and switching costs. - **International expansion, especially Europe** (medium-term) — The company is highly U.S.-concentrated and sees overseas markets as a long-term growth lever. - Expand manufacturing capacity through automation and facility investment - Shorten turnaround times to reinforce the custom-product value proposition - Protect customer retention through quality systems and service - Grow beyond the U.S. by building European distribution and market access - Consider localized manufacturing or acquisitions to accelerate expansion - Broaden exposure to high-growth areas such as cell and gene therapy ## Risks Teknova remains exposed to operating losses, competitive pressure, and the cyclicality of biotech and diagnostics demand. Because customers depend on their own regulatory approvals, funding, and market adoption, Teknova can see demand weaken when end markets slow or when customers delay programs. The company also faces execution risk in scaling manufacturing, maintaining quality, and delivering short turnaround times, since those factors are central to its value proposition. International expansion, acquisitions, and cybersecurity are additional risks because they can introduce integration complexity, unfamiliar operating environments, and operational disruption. - **Dependence on customer program success** [high] — Teknova sells inputs to customers whose own products must win regulatory approval and market acceptance. - **Operating losses and financing needs** [high] — The company has incurred losses and may need continued capital to fund operations and expansion. - **Competitive pressure and in-house substitution** [medium] — Customers may choose larger competitors or produce similar reagents internally if it is cheaper or more convenient. - **Manufacturing and supply chain disruption** [high] — Short turnaround times and quality consistency are core to the business, so any disruption can affect delivery and retention. - **Cybersecurity incident** [medium] — A breach could interrupt operations, impair systems, or damage reputation and customer trust. - **International expansion and acquisition execution** [medium] — Entering new markets or integrating acquisitions can create operational and financial complexity without guaranteed payoff. - Customer demand depends on the success of customers' own drug and diagnostics programs - Biotech funding and healthcare reimbursement changes can reduce purchasing activity - Competition from larger suppliers and in-house customer production can pressure pricing - Manufacturing or quality failures could damage customer trust and recurring orders - International expansion and acquisitions may be difficult to integrate and execute - Cyberattacks could disrupt operations and compromise sensitive systems ## Accounting Revenue recognition is a key accounting judgment because Teknova sells custom and made-to-order products, so management must determine when performance obligations are satisfied under ASC 606. The business also has meaningful quarter-to-quarter variability tied to customer ordering patterns and product mix, which can make revenue and gross margin comparisons noisy. Inventory valuation matters because the company disclosed non-recurring charges in 2024 related to expired inventory disposal, showing that obsolescence and write-down risk can affect reported gross profit. Lease accounting is also important because the company has office, manufacturing, warehouse, and distribution leases that create ongoing balance-sheet liabilities and cash commitments. As an emerging growth company with stock-based compensation and financing activity, investors should also watch how non-cash expenses and capital raises affect reported earnings and cash flow. - **Revenue recognition for custom orders** — Can shift revenue timing between periods - **Inventory valuation and obsolescence** — Affects cost of sales and gross margin - **Lease accounting** — Affects balance sheet leverage and fixed-cost visibility - **Stock-based compensation** — Affects operating income and earnings comparability - ASC 606 revenue recognition for custom and made-to-order products - Quarterly revenue and margin volatility from customer ordering patterns - Inventory obsolescence and write-downs can affect gross profit - Operating lease accounting for manufacturing and distribution facilities - Stock-based compensation and other non-cash charges affect reported losses - Financing transactions can change liquidity without reflecting operating performance --- *Last updated: 2026-08-11T04:46:20.116783+00:00*